| Drinking History | Non-drinker |
| Race | Caucasian |
| Stage of disease | IV |
| Date of Draw | 2024/4/12 |
| Grade | G3 |
| Volume | 1.5 mL |
| Location Country | Ukraine |
| Smoking History | Non-smoker |
| Lab Tests | CBC: 12-Apr-2024: RBC: 4.1*1012/L; HGB: 144 g/L; PLT: 296*109/L; WBC: 7.1*109/L; NEU: 60%; LYM: 40%; ESR: 40 mm/hour; Biochemistry: 12-Apr-2024: ALAT: 40 U/L; ASAT: 26 U/L; Creatinine: 98 μmol/L; Total bilirubin: 20 μmol/L; Direct bilirubin: 9 μmol/L; Urea: 5.6 μmol/L; Total cholesterol: 4.6 μmol/L; HDL: 1.3 μmol/L; LDL: 2.6 μmol/L; Total protein: 71 g/L; Glucose: 3.9 mmol/L |
| N (Node) | pN0 |
| Date of diagnosis | 2020/9/2 |
| Clinical diagnosis | TNBC: Invasive carcinoma of no special type (NST) |
| T (Tumor) | pT2 |
| Processing | Single spin |
| Pathology Report | Invasive carcinoma of no special type (NST) of the right breast, tumor size: 2.5 cm x 3.0 cm x 2.0 cm. Mts: skin of the anterior chest wall, satellite nodes in both mammary glands, liver, axillary, mediastinal lymph nodes. |
| Treatment | Surgery: 26-Aug-2020: Lumpectomy of the right breast with lymph node dissection; Chemotherapy: 18 courses: Paclitaxel, i/v; Carboplatin, i/v; Docetaxel, i/v; Cyclophosphamide, i/v; Gemcitabine, i/v, from 21-Sep-2020 to 12-Apr-2024; Radiotherapy: 50 Gy to the right breast, cervical, supraclavicular and infraclavicular lymph nodes, from 15-Jan-2021 to 22-Feb-2021 |
| M (Metastasis) | cM1 |
| COVID-19 Vaccination | Vaccinated: Pfizer, 2 doses |
| HIV, HBV, HCV, RPR | Negative |
| Treatment of Concomitant Diseases | No |
| Biomarkers | 2-Sep-2020: ER negative; PR negative; Her2 negative; Ki-67 45% |
| Weight, kg | 68 |
| Height, cm | |
| Concomitant Diseases | No |
| Cancer History and Relapses | Prolongation Morbi: 4-Apr-2024: metastases to the skin of the anterior chest wall, satellite nodes in both mammary glands, liver, axillary, mediastinal lymph nodes were detected |
